Boehringer Announces $650M Pradaxa Settlement for Bleeding Victims

Top Class Actions’s website and social media posts use affiliate links. If you make a purchase using such links, we may receive a commission, but it will not result in any additional charges to you. Please review our Affiliate Link Disclosure for more information.

German drug maker Boehringer Ingelheim announced yesterday that it has reached a $650 million “comprehensive settlement” to resolve close to 4,000 Pradaxa lawsuits alleging serious bleeding injuries caused by the drug. Plaintiffs stand to receive more than $160,000 from the proposed Pradaxa settlement if it’s divided equally.

The popular blood thinner has netted billions of dollars for Boehringer Ingelheim. As a competitor to the generic blood thinning medication warfarin, the supposed benefits of Pradaxa are that patients don’t have to get frequent blood testing and there are fewer interactions with other drugs. The company also alleges that Pradaxa internal bleeding side effects occur at a lower rate than with warfarin (Coumadin).

Thousands of Pradaxa lawsuits consolidated into multidistrict litigation cast doubt on those claims. Pradaxa class action lawsuit attorneys and scores of Pradaxa bleeding victims allege that both Boehringer Ingelheim and the federal Food and Drug Administration are not adequately addressing the fact that no antidote for bleeding exists for patients taking Pradaxa. If a patient on warfarin starts hemorrhaging, doctors in the emergency room can administer potassium. There are no reversal agents for Pradaxa internal bleeding side effects, leading to hundreds of deaths each year it has been on the market.

In fact, a recent complaint among the thousands of Pradaxa lawsuits filed in state and federal courts notes that the clinical trial used to obtain FDA approval noted “a higher rate of major gastrointestinal bleeds” for Pradaxa compared to warfarin and a “similar rate of major bleeds.” In spite of that, there is no black-box warning regarding the potential fatal consequences of using the medication nor clear labeling, the Pradaxa lawsuit suggests. The adverse evens, in fact, occur at a higher rate than strokes or embolisms Pradaxa is supposed to treat, affecting 1 in 100 patients.

Since the Pradaxa settlement talks are in the very early stages, many questions remain. For example, while the $650 million in total funding would result in each plaintiff receiving about $160,000, there could be tiers based on the level of injury or if the alleged Pradaxa bleeding injury led to someone’s death. There also remains the question of whether or not Pradaxa class action lawsuit attorneys involved in the litigation would consider it adequate compensation for clients.

Join a Free Pradaxa Class Action Lawsuit Investigation

If you or a loved one were medically diagnosed with internal bleeding problems after using Pradaxa, you may be able to take legal action against the drug’s manufacturer and pursue a share of future Pradaxa settlement negotiations. Joining a Pradaxa class action lawsuit or filing an individual Pradaxa lawsuit may help you recover compensation for medical bills, pain and suffering, and other damages. Obtain a free case evaluation now:

Oops! We could not locate your form.